China Resources Pharmaceutical Group Ltd
HKEX:3320
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.51
6.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
China Resources Pharmaceutical Group Ltd
Income from Continuing Operations
China Resources Pharmaceutical Group Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Income from Continuing Operations
HK$13.3B
|
CAGR 3-Years
32%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Income from Continuing Operations
HK$2.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Income from Continuing Operations
¥2.9B
|
CAGR 3-Years
37%
|
CAGR 5-Years
27%
|
CAGR 10-Years
18%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Income from Continuing Operations
¥4.9B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
12%
|
|
|
C
|
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
|
Income from Continuing Operations
¥993.3m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
12%
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Income from Continuing Operations
-$42.2m
|
CAGR 3-Years
37%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
China Resources Pharmaceutical Group Ltd
Glance View
In the vast and dynamic landscape of China's healthcare sector, China Resources Pharmaceutical Group Ltd. has emerged as a formidable player. Born from the rich heritage of its parent conglomerate, China Resources Holdings, the company weaves together a complex tapestry of pharmaceutical manufacturing, distribution, and retail operations. Its diversified operations ensure that it maintains a robust footprint across the entire pharmaceutical value chain. The company's manufacturing arm is a powerhouse, producing a vast array of products, including traditional Chinese medicine and modern pharmaceuticals, catering to the diverse needs of health consumers in China and beyond. Leveraging its extensive industry expertise and a deep understanding of the local market, China Resources Pharmaceutical crafts products that blend innovation with time-honored traditions, effectively meeting the growing demands for quality healthcare solutions. On the distribution and retail front, China Resources Pharmaceutical Group employs its extensive and well-integrated network to efficiently channel its products across the nation. The strategic positioning of its distribution centers enables it to serve hundreds of thousands of pharmacies, hospitals, and healthcare institutions, ensuring broad accessibility. Retail operations round out the company's comprehensive approach, with a wide-reaching chain of drugstores under its banner offering not only medicinal products but also healthcare services. This holistic business model not only diversifies revenue streams but also strengthens the company's ability to weather industry shifts, making it a resilient entity in the ever-evolving pharmaceutical and healthcare milieu. Through its multifaceted approach, China Resources Pharmaceutical Group Ltd. continues to play a crucial role in shaping the future of healthcare in China, navigating challenges and opportunities with the acuity expected of an industry leader.
See Also
What is China Resources Pharmaceutical Group Ltd's Income from Continuing Operations?
Income from Continuing Operations
13.3B
HKD
Based on the financial report for Jun 30, 2024, China Resources Pharmaceutical Group Ltd's Income from Continuing Operations amounts to 13.3B HKD.
What is China Resources Pharmaceutical Group Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
10%
Over the last year, the Income from Continuing Operations growth was 14%. The average annual Income from Continuing Operations growth rates for China Resources Pharmaceutical Group Ltd have been 32% over the past three years , 10% over the past five years .
You don't have any saved screeners yet
